"Pain Points and the Power of Perseverance: The MindLab Story" - Interview with Larry Raoul James

"The Future ETF of Early-Stage Investments" - Interview with Tom Vogelsong

"Family Matters in Fundraising" - Interview with Dr. Erick Gamelin

"Embracing the Early-Stage Journey" - Interview with David Dlesk

"Digital Partnering for Fundraising and Licensing Deals Isn’t Going Anywhere in 2022"

"Making a Difference One Impression at a Time" - Interview with Diana Caldwell

Bold Therapeutics is a clinical-stage pharma startup developing and commercializing novel therapeutics to combat drug resistance in cancer and infectious disease. At Digital RESI March, Bold Therapeutics founder Russell McAllister met success at the Innovator’s Pitch Challenge (IPC) and is sharing his perspectives from preparation to pitch to follow-up conversations. If you’re actively fundraising or considering pitching at RESI, check out our conversation and learn how Russell leveraged, not only his company, but his own unique experience to stand out at RESI.

"Preparing to Pitch with the End in Mind" - Interview with E. Russell McAllister

Today, we are excited to feature Dr. Sharon Hesterlee, Executive Vice President and Chief Research Officer at the Muscular Dystrophy Association (MDA), a title sponsor at our upcoming RESI Boston conference. Dr. Hesterlee plays a vital role in advancing research and treatment for neuromuscular diseases. In this interview, she discusses MDA's investment programs, including the MOVR Data Hub and Venture Philanthropy, and shares insights on supporting biotech startups, key criteria for funding ultra-rare disease therapies, and emerging trends in research. Join us as Dr. Hesterlee offers valuable advice for entrepreneurs seeking to make an impact in the neuromuscular disease landscape.

Innovations in Neuromuscular Disease: A Conversation with Dr. Sharon Hesterlee

Bilix, recognized as a top Innovator’s Pitch Challenge winner at RESI Boston this past September, is making waves in the biotech space with its innovative multi-modality approach to inflammatory and autoimmune diseases. In this interview, Myung Kim, Founder and CEO, shares how participating in RESI Boston helped the company connect with key investors, refine its strategy, and advance its clinical milestones.

Hear firsthand how Bilix is driving progress in complex disease treatment and discover how your company can join the next generation of innovators pitching at RESI London and RESI JPM. Applications are now open.

Life Science Nation

Popular tracks